Home›Pirfenidone Capsule 267 Mg›Pirfenidone Capsule 267 Mg + Fluvoxamine

Does Pirfenidone Capsule 267 Mg Interact with Fluvoxamine?

CDI records a major classification for Pirfenidone Capsule 267 Mg and Fluvoxamine. The stored summary is: Strong CYP1A2 inhibitor significantly increases pirfenidone exposure. Concomitant use is not recommended; discontinue fluvoxamine prior to pirfenidone administration or reduce pirfenidone to 267 mg three times daily. The mechanism involves cyp1a2 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.

Stored CDI classification
Major
Pirfenidone Capsule 267 Mg Class
Pyridone
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

CYP1A2 inhibition

What To Tell Your Doctor or Pharmacist

If you are taking Pirfenidone Capsule 267 Mg and your doctor is considering prescribing Fluvoxamine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Pirfenidone Capsule 267 Mg(Esbriet)+💊 Fluvoxamine

Severity & Interaction Details

⚠️
major
Stored CDI classification: major
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
Pyridone
Drug B class
—
Source
NLP:pirfenidone capsule, 267 mg

What this means in plain English

Strong CYP1A2 inhibitor significantly increases pirfenidone exposure. Concomitant use is not recommended; discontinue fluvoxamine prior to pirfenidone administration or reduce pirfenidone to 267 mg three times daily.

About Pirfenidone Capsule 267 Mg and Fluvoxamine

Pirfenidone Capsule 267 Mg is a Pyridone. Pirfenidone Capsule 267 Mg is also sold under the brand name Esbriet.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:pirfenidone capsule, 267 mg

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Pirfenidone Capsule 267 Mg and Fluvoxamine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations